Dopamine D3 receptor antagonists as therapeutic agents

Drug Discovery Today

Volumn 10, Issue 13, 2005, Pages 917-925

  Joyce, Jeffrey N ^a   Millan, Mark J ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 1,2,3,4 TETRAHYDRO 6 (4 METHOXYPHENYLSULFONYLMETHYL)NAPHTHALENE; 2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4' ACETYL N [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BIPHENYL 4 CARBOXAMIDE; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; A 437203; ATYPICAL ANTIPSYCHOTIC AGENT; AVE 5997; BP 897; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; L 741626; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NAFADOTRIDE; NEUROLEPTIC AGENT; PNU 177864; RACLOPRIDE; S 23199; S 33084; S 33138; UNCLASSIFIED DRUG; DOPAMINE RECEPTOR BLOCKING AGENT; NITRILE; TETRAHYDROISOQUINOLINE DERIVATIVE;

BEHAVIOR; BRAIN REGION; CLINICAL TRIAL; COGNITION; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HYPOTHERMIA; LIMBIC SYSTEM; MOLECULAR CLONING; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; POSITIVE SYNDROME; POSTSYNAPTIC MEMBRANE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; THALAMUS; WILD TYPE; ADDICTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METHODOLOGY; PATHOPHYSIOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; DOPAMINE ANTAGONISTS; HUMANS; MOLECULAR STRUCTURE; NITRILES; RECEPTORS, DOPAMINE D3; SUBSTANCE-RELATED DISORDERS; TECHNOLOGY, PHARMACEUTICAL; TETRAHYDROISOQUINOLINES;

EID: 21544439847     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03491-4     Document Type: Review

References (87)

1. Neve K.A. Dopamine receptor signaling J. Recept. Signal Transduct. Res. 24 2004 165 205
2. 3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′- O-(3-[35s]thio)-triphosphate binding and antibody study Mol. Pharmacol. 55 1999 564 574
3. 3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase c-dependent mechanism Mol. Pharmacol. 56 1999 1025 1030
4. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs Pharmacol. Ther. 90 2001 231 259
5. Maggio R. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, Pramipexole and Ropinirole J. Neurochem. 87 2003 631 641
6. 3 receptor interactions: evidence of functional A2a/D3 heteromeric complexes Mol. Pharmacol. 67 2005 400 407
7. 2 receptor expressing neurons Neuropsychopharmacology 20 1999 60 80
8. 3 receptor in schizophrenia and in antipsychotic drug actions Brain Res. Brain Res. Rev. 31 2000 277 287
9. 3 receptors expressed by all mesencephalic dopamine neurons J. Neurosci. 20 2000 8677 8684
10. 2 dopamine receptor mRNA Brain Res. Mol. Brain Res. 10 1991 283 289
11. Zapata A., Shippenberg T.S. D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens J. Neurochem. 81 2002 1035 1042
12. 3-preferring agonist (+)-Pd 128907 on dialysate dopamine levels Neuropharmacology 48 2005 43 50
13. Holmes A. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes Neuropharmacology 47 2004 1117 1134
14. 3 receptor-selective agonists and antagonists Synapse 31 1999 210 215
15. 3 knock-out and wild-type mice Neuropharmacology 38 1999 555 565
16. 3 receptor knockout mice Pharmacol. Biochem. Behav. 76 2003 551 562
17. 3 receptor agonists and antagonists Mini Rev. Med. Chem. 1 2001 89 99
18. Luedtkea R.R., Mach R.H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders Curr. Pharm. Des. 9 2003 643 671
19. Audinot V. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, Nafadotride, Gr 103,691 and U 99194 J. Pharmacol. Exp. Ther. 287 1998 187 197
20. 3 receptor antagonist CNS Drug Rev. 4 1998 42 53
21. Millan M.J. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats Psychopharmacology 174 2004 341 357
22. 3-receptors: I. receptorial, electrophysiological and neurochemical profile compared with Gr218,231 and L741,626 J. Pharmacol. Exp. Ther. 293 2000 1048 1062
23. Millan M.J. S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-Receptors: Ii. functional and behavioural profile compared with Gr218,231 and L741,626 J. Pharmacol. Exp. Ther. 293 2000 1063 1073
24. 3 receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 294 2000 1154 1165
25. Gyertyan I., Saghy K. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in Nmri mice and Wistar rats: comparative study with nafadotride, U 99194a and SB 277011 Behav. Pharmacol. 15 2004 253 262
26. 2-like receptor stable cell lines coupled to calcium flux through Galpha(Qo5) Biochem. Pharmacol 68 2004 761 772
27. Chaperon F. Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors Neuropharmacology 44 2003 1047 1053
28. 3 receptor agonist Nature 400 1999 371 375
29. 3 dopamine receptor partial agonist Bp897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys J. Pharmacol. Exp. Ther. 311 2004 770 777
30. Wicke K., Garcia-Ladona J. The dopamine D3 receptor partial agonist, Bp 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors Eur. J. Pharmacol. 424 2001 85 90
31. 3 receptor partial agonist, Bp897, is a potent ligand at diverse adrenergic and serotonergic receptors Am. Soc. Neurosci. 26 2000 2154
32. Vonderfecht S.L. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence Toxicol. Pathol. 32 2004 318 325
33. 3 receptor antagonist A-437203 Am. Soc. Neurosci. 2002 894.6
34. 3 receptors: functional profile in rodent models of the control of negative-cognitive symptoms of schizophrenia Int. J. Neuropsychopharm. 7 2004 S265
35. Dubuffet T. Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist Bioorg. Med. Chem. Lett. 9 1999 2059 2064
36. Millan M.J. N-Methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review Curr. Drug Targets. CNS. Neurol. Disord. 1 2002 191 213
37. Mogenson G.J. Influence of dopamine on limbic inputs to the nucleus accumbens Ann. N. Y. Acad. Sci. 537 1988 86 100
38. 3 receptors and use of antipsychotics in patients with schizophrenia. a postmortem study Arch. Gen. Psychiatry 54 1997 225 232
39. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period Synapse 40 2001 137 144
40. Abi-Dargham A., Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies Eur. Psychiatry 20 2005 15 27
41. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors Prog. Neuropsychopharmacol. Biol. Psychiatry 27 2003 1081 1090
42. 3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc. Natl. Acad. Sci. U. S. A. 94 1997 3363 3367
43. Spielewoy C. Increased rewarding properties of morphine in dopamine-transporter knockout mice Eur. J. Neurosci. 12 2000 1827 1837
44. Joyce J.N. Methamphetamine-induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations Synapse 52 2004 11 19
45. 3 receptor expression and triggers behavioural sensitization Nature 411 2001 86 89
46. Dawson N.M. Changes In the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment Synapse 39 2001 70 81
47. Dubertret C. Meta-analysis of Drd3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians Am. J. Med. Genet. 81 1998 318 322
48. 3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis Psychiatr. Genet. 13 2003 1 12
49. 3 receptor-gene-not-associated-with- symptomatology-of-major-psychoses Am. J. Med. Genet. 88 1999 476 480
50. Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia - an update Pharmacogenomics 5 2004 691 698
51. Staddon S. Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population Schizophr. Res. 73 2005 49 54
52. Reynolds G.P. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-Ht2c receptor polymorphisms separately associate with positive and negative symptom response Eur. Neuropsychopharmacol. 15 2005 143 151
53. 3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate Exp. Neurol. 188 2004 128 138
54. 3 receptor function Nat. Med. 9 2003 762 767
55. Kay S.R. The positive and negative syndrome scale (Panss) for schizophrenia Schizophr. Bull. 13 1987 261 276
56. 3 receptor in reactivity to cocaine-associated cues in mice Eur. J. Neurosci. 15 2002 2016 2026
57. Siuciak J.A., Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors Psychopharmacology 175 2004 163 169
58. Robertson G.S., Fibiger H.C. Neuroleptics increase C-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine Neuroscience 46 1992 315 328
59. 3 receptor selective Rgh-1756 Neuropharmacology 40 2001 383 393
60. Robertson G.S. Clozapine-, but not haloperidol-, induced increases in ΔFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors Eur. J. Neurosci. 20 2004 3189 3194
61. Ichikawa J. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325 339
62. Hironaka N. Memory-related acetylcholine efflux from rat prefrontal cortex and hippocampus: a microdialysis study Brain Res. 901 2001 143 150
63. Hill K. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies Acta Psychiatr. Scand. 110 2004 243 256
64. Pantelis C. Relationship of behavioural and symptomatic syndromes in schizophrenia to spatial working memory and attentional set-shifting ability Psychol. Med. 34 2004 693 703
65. Dean B., Scarr E. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits Curr. Drug Targets. CNS. Neurol. Disord. 3 2004 217 225
66. 3 receptors enhances frontocortical cholinergic transmission and cognitive function in rats Soc. Neurosci. Abstr. 29 2004 776.4
67. Lacroix L.P. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex Neuropsychopharmacology 28 2003 839 849
68. 3 receptor antagonists improve the learning performance in memory-impaired rats Psychoxspharmacology (Berl.) 179 2005 567 575
69. Glickstein, S.B. et al. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb. Cortex (in press)
70. Meltzer H.Y. Cognitive factors in schizophrenia: causes, impact, and treatment CNS Spectr. 9 2004 15 24
71. Steele T.D. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats Pharmacol. Biochem. Behav. 58 1997 477 483
72. Stip E. On the trail of a cognitive enhancer for the treatment of schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 219 232
73. Carlsson A. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence Annu. Rev. Pharmacol. Toxicol. 41 2001 237 260
74. O'Neill M.F., Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, Mk-801 and the dopamine D1 agonist C-Apb in mice Psychopharmacology 145 1999 237 250
75. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade Neuropharmacology 45 2003 174 181
76. Meincke U. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis-a longitudinal study Eur. Arch. Psychiatry Clin. Neurosci. 254 2004 415 421
77. 3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice J. Neurosci. 19 1999 4627 4633
78. 3 receptor antagonist A-437203 on the development and expression of locomotor sensitization to quinpirole in rats Am. Soc. Neurosci. 30 2004 350.1
79. 3 receptor antagonist J. Med. Chem. 46 2003 4952 4964
80. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons J. Neurosci. 3 1983 1607 1619
81. Richtand N.M. D3 Dopamine receptor, behavioral sensitization, and psychosis Neurosci. Biobehav. Rev. 25 2001 427 443
82. Tsapakis E. Does dopamine sensitization underlie the association between schizophrenia and drug abuse? Curr. Opin. Psychiatry 16 2003 S45 S52
83. 3 Receptors inhibits stress-induced reinstatement of cocaine-seeking in rats Psychopharmacology 176 2004 57 65
84. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats J. Neurosci. 22 2002 9595 9603
85. 3 receptor antagonist SB-277011a blocks the acquisition and expression of the conditioned place preference response to heroin in male rats Synapse 48 2003 154 156
86. Beardsley P.M. The D3R partial agonist, Bp 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered Behav. Pharmacol. 12 2001 1 11
87. Millan M.J. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1- yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at 1- and 2-adrenergic receptors: Ii. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents J. Pharmacol. Exp. Ther. 292 2000 54 66